Uptravi and Primary pulmonary hypertension - a phase IV clinical study of FDA data
Primary pulmonary hypertension is found among people who take Uptravi, especially for people who are female, 60+ old, have been taking the drug for < 1 month.
The phase IV clinical study analyzes which people take Uptravi and have Primary pulmonary hypertension. It is created by eHealthMe based on reports of 22,185 people who have side effects when taking Uptravi from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
22,185 people reported to have side effects when taking Uptravi.
Among them, 1,649 people (7.43%) have Primary pulmonary hypertension.
What is Uptravi?
Uptravi has active ingredients of selexipag. eHealthMe is studying from 22,187 Uptravi users for its effectiveness, alternative drugs and more.
What is Primary pulmonary hypertension?
Primary pulmonary hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart) is found to be associated with 1,176 drugs and 745 conditions by eHealthMe.
Number of Uptravi and Primary pulmonary hypertension reports submitted per year:
Time on Uptravi when people have Primary pulmonary hypertension *:
Gender of people who have Primary pulmonary hypertension when taking Uptravi*:
Age of people who have Primary pulmonary hypertension when taking Uptravi *:
Common drugs people take besides Uptravi *:
Common side effects people have besides Primary pulmonary hypertension *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Uptravi and have Primary pulmonary hypertension?Check whether Primary pulmonary hypertension is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Primary pulmonary hypertension and when was it recovered:
Expand to all the drugs that have ingredients of selexipag:
Alternative drugs to, pros and cons of Uptravi:
- Uptravi (22,187 reports)
Common Uptravi side effects:
Browse all side effects of Uptravi:a b c d e f g h i j k l m n o p q r s t u v w x y z
Primary pulmonary hypertension treatments and more:
- Primary pulmonary hypertension (200,567 reports)
COVID vaccines that are related to Primary pulmonary hypertension:
- Primary pulmonary hypertension in Moderna COVID Vaccine
- Primary pulmonary hypertension in Pfizer BioNTech Covid Vaccine
- Primary pulmonary hypertension in Johnson and Johnson Covid Vaccine
Common drugs associated with Primary pulmonary hypertension:
All the drugs that are associated with Primary pulmonary hypertension:
- Primary pulmonary hypertension (1,176 drugs)
Common conditions associated with Primary pulmonary hypertension:
All the conditions that are associated with Primary pulmonary hypertension:
- Primary pulmonary hypertension (745 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on selexipag (the active ingredients of Uptravi) and Uptravi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Stiolto Respimat and Urinary Incontinence Aggravated - 4 seconds ago
- Hyperkalemia and drugs of ingredients of fish oil - 8 seconds ago
- Xylocaine and Urinary Tract Infection - 11 seconds ago
- Truvada and Genital Lesion - 14 seconds ago
- Flomax and Vascular Pseudoaneurysm - 19 seconds ago
- Probiotic and Muscle Spasticity - 28 seconds ago
- Neurontin and Cardiac Failure Aggravated - 29 seconds ago
- Mucinex and Jaundice - Yellow Skin - 32 seconds ago
- Mircette and Gallbladder Disorder - 36 seconds ago
- Thyroid Diseases in Ramipril, how severe and when it was recovered? - 36 seconds ago